Earkart Completes US FDA Registration for Hearing Aid Portfolio

By The Indus Pulse Editorial Team3 min read
Two white medical hearing aid devices resting on a white tray surrounded by metallic medical instruments
AI illustrationCreated for The Indus Pulse with AI tools

Earkart Limited, an Indian hearing-care technology firm, has finished its US Food and Drug Administration (FDA) establishment registration and obtained active device listings for its hearing aid range. While LiveMint reported on November 20, 2026 that the FDA listings cover four hearing aid categories, financial news platform scanx.trade reported five cleared categories in its breakdown of the November 20 announcement.

Listed Categories and Product Models

LiveMint reported that the listed range covers four segments: OTC Hearing Aids, Prescription Hearing Aids, Wireless OTC Hearing Aids, and Wireless Prescription Hearing Aids. By contrast, scanx.trade detailed five categories: Air-Conduction Prescription models (Fame FA221, Fame P FA222, Fame SP FA223, Fame 2T FA224, and Fort UP FA225), Air-Conduction OTC models (PACE PA16531, SPIN SP16431, and Radius 8, 12, and 16 variants), Wireless OTC models (CURV CU16631 and EQFY EQB2302), Wireless Prescription model CORE CO16731, and Master Hearing Aid TINY TY16831. According to scanx.trade, offering multiple OTC SKUs such as the Radius series with varying battery capacities or features points to a tiered pricing or feature approach rather than a single-product entry. Earkart said the registrations give it a foundation to explore US partnerships, distribution arrangements, and market-entry strategies, though actual commercialisation and sales remain subject to applicable product-specific regulatory requirements.

Omni Ecosystem and US Market Context

In a statement cited by LiveMint, Earkart described completing its US FDA registration and securing active device listings across four categories as a key step in its international expansion. The company develops, manufactures, and distributes hearing aids and audiology equipment, and intends to use its indigenous product development capabilities to explore affordable hearing device offerings in the United States. Earkart's Omni business model links full-stack hearing diagnosis with remote hearing aid programming and earKART-branded devices, aiming to build a comprehensive hearing healthcare platform that improves access to hearing solutions.

According to Emergen Research cited by LiveMint, the US hearing aids market is projected to grow from $4.65 billion in 2026 to $9.57 billion by 2035 at an 8.4% compound annual growth rate, while Global Market Insights estimates the US OTC segment will rise from $310.6 million to $690.8 million over the same period. Separately, scanx.trade noted that Earkart's filing did not disclose revenue or profit margin metrics, and reported historical stock returns of 0.0% over 1 day, -7.19% over 5 days, 0.0% over 1 month, -20.93% over 6 months, -50.20% over 1 year, and -28.30% over 5 years. According to Kotak Neo, Earkart Limited's export sales contributed 0.80%, 0.35%, and 0.08% of revenue from sale of products for fiscal 2025, fiscal 2024, and fiscal 2023, respectively.

Background

Class II devices are not exempt from FDA Good Manufacturing Practice (GMP) requirements, according to the U.S. Food and Drug Administration.

From October 11–13, 2025, Earkart Limited participated in an otolaryngology conference in Indianapolis, USA, according to Earkart Limited.

Spotted an error in this article? Tell us and we will check it.